• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

B-cell maturation antigen expression and clinical features of plasmablastic lymphoma.

作者信息

Dong Ning, Zhang Hailing, Song Jinming, Mammadova Jamila, Shah Bijal, Saeed Hayder, Gaballa Sameh, Grajales-Cruz Ariel, Isenalumhe Leidy, Bello Celeste, Sokol Lubomir, Pinilla Javier, Chavez Julio

机构信息

Department of Malignant Hematology H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA.

University of South Florida Morsani College of Medicine Tampa Florida USA.

出版信息

EJHaem. 2024 Jan 18;5(1):285-289. doi: 10.1002/jha2.807. eCollection 2024 Feb.

DOI:10.1002/jha2.807
PMID:38406544
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10887266/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/564a/10887266/42cd1b7b377c/JHA2-5-285-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/564a/10887266/42cd1b7b377c/JHA2-5-285-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/564a/10887266/42cd1b7b377c/JHA2-5-285-g001.jpg

相似文献

1
B-cell maturation antigen expression and clinical features of plasmablastic lymphoma.浆母细胞淋巴瘤的B细胞成熟抗原表达及临床特征
EJHaem. 2024 Jan 18;5(1):285-289. doi: 10.1002/jha2.807. eCollection 2024 Feb.
2
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.BCMA CAR-T 可诱导难治性浆母细胞淋巴瘤完全和持久缓解。
J Immunother Cancer. 2023 May;11(5). doi: 10.1136/jitc-2023-006684.
3
Plasmablastic lymphoma: An update.弥漫性大 B 细胞淋巴瘤：更新。
Int J Lab Hematol. 2022 Sep;44 Suppl 1(Suppl 1):54-63. doi: 10.1111/ijlh.13863.
4
Clinicopathologic features and abnormal signaling pathways in plasmablastic lymphoma: a multicenter study in China.浆母细胞淋巴瘤的临床病理特征和异常信号通路：中国多中心研究。
BMC Med. 2022 Dec 15;20(1):483. doi: 10.1186/s12916-022-02683-9.
5
[Plasmablastic lymphoma presenting clinical symptoms similar to plasmablastic myeloma].表现出与浆母细胞性骨髓瘤相似临床症状的浆母细胞性淋巴瘤
Rinsho Ketsueki. 2023;64(4):260-264. doi: 10.11406/rinketsu.64.260.
6
Unraveling the molecular landscape: a comparative analysis of PI3K and MAPK signaling pathways in plasmablastic lymphoma and diffuse large B-cell lymphoma with therapeutic implications.解析分子图谱：浆母细胞淋巴瘤和弥漫性大 B 细胞淋巴瘤中 PI3K 和 MAPK 信号通路的比较分析及其治疗意义。
Hum Pathol. 2023 Nov;141:102-109. doi: 10.1016/j.humpath.2023.07.009. Epub 2023 Jul 29.
7
Cytokeratin expression in plasmablastic lymphoma - a possible diagnostic pitfall in the routine work-up of tumours.浆母细胞性淋巴瘤中细胞角蛋白的表达 - 常规肿瘤检查中的一个潜在诊断陷阱。
Histopathology. 2021 May;78(6):831-837. doi: 10.1111/his.14300. Epub 2020 Dec 25.
8
Identification of Potential Therapeutic Targets for Plasmablastic Lymphoma Through Gene Expression Analysis: Insights into RAS and Wnt Signaling Pathways.通过基因表达分析鉴定浆母细胞淋巴瘤的潜在治疗靶点：对 RAS 和 Wnt 信号通路的深入了解。
Mod Pathol. 2023 Aug;36(8):100198. doi: 10.1016/j.modpat.2023.100198. Epub 2023 Apr 25.
9
From the archives of MD Anderson Cancer Center: Plasmablastic lymphoma presenting as a kidney mass in an immunocompetent patient: Case report and literature review.从 MD 安德森癌症中心档案库：浆母细胞淋巴瘤表现为免疫功能正常患者的肾脏肿块：病例报告和文献复习。
Ann Diagn Pathol. 2023 Dec;67:152186. doi: 10.1016/j.anndiagpath.2023.152186. Epub 2023 Jul 29.
10
Plasmablastic lymphoma: current knowledge and future directions.浆母细胞淋巴瘤：当前的认识和未来方向。
Front Immunol. 2024 Feb 13;15:1354604. doi: 10.3389/fimmu.2024.1354604. eCollection 2024.

引用本文的文献

1
The Genetic and Epigenetic Alterations of Plasmablastic Lymphoma: A Narrative Review.浆母细胞淋巴瘤的遗传和表观遗传改变：一篇综述
Cancers (Basel). 2025 Jun 9;17(12):1914. doi: 10.3390/cancers17121914.
2
[Chinese expert consensus on the diagnosis and treatment of plasmablastic lymphoma (2025)].[2025年浆母细胞淋巴瘤诊断与治疗中国专家共识]
Zhonghua Xue Ye Xue Za Zhi. 2025 Apr 14;46(4):295-301. doi: 10.3760/cma.j.cn121090-20241213-00566.
3
Netrin-1 and B-cell maturation antigen expression in a large cohort of 361 lymphomas: sensitive and specific staining in plasmablastic lymphomas, and therapeutic perspectives.

本文引用的文献

1
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.BCMA CAR-T 可诱导难治性浆母细胞淋巴瘤完全和持久缓解。
J Immunother Cancer. 2023 May;11(5). doi: 10.1136/jitc-2023-006684.
2
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study.局限性期浆母细胞淋巴瘤患者的结局：一项多机构回顾性研究。
Am J Hematol. 2023 Feb;98(2):300-308. doi: 10.1002/ajh.26784. Epub 2023 Jan 1.
3
Teclistamab in Relapsed or Refractory Multiple Myeloma.特卡昔单抗治疗复发或难治性多发性骨髓瘤。
361例淋巴瘤大样本队列中Netrin-1和B细胞成熟抗原的表达：浆母细胞淋巴瘤中的敏感且特异染色及治疗前景
J Pathol Clin Res. 2025 May;11(3):e70027. doi: 10.1002/2056-4538.70027.
4
Meta-analysis of the comparative efficacy and safety of new drugs in combination with chemotherapy in primary plasmoblastic lymphoma.新药联合化疗治疗原发性浆母细胞淋巴瘤的疗效和安全性的Meta分析
Clin Exp Med. 2025 Apr 1;25(1):103. doi: 10.1007/s10238-025-01636-9.
N Engl J Med. 2022 Aug 11;387(6):495-505. doi: 10.1056/NEJMoa2203478. Epub 2022 Jun 5.
4
Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma.达雷妥尤单抗联合异环磷酰胺、卡铂和依托泊苷治疗复发的浆母细胞淋巴瘤。
Br J Haematol. 2022 Jul;198(2):e32-e34. doi: 10.1111/bjh.18228. Epub 2022 May 4.
5
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.西达基奥仑赛，一种针对 B 细胞成熟抗原的嵌合抗原受体 T 细胞疗法，用于治疗复发或难治性多发性骨髓瘤患者（CARTITUDE-1）：一项 1b/2 期开放标签研究。
Lancet. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24.
6
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.伊达比星脂质体注射用多柔比星治疗复发/难治性多发性骨髓瘤
N Engl J Med. 2021 Feb 25;384(8):705-716. doi: 10.1056/NEJMoa2024850.
7
The Emerging Treatment Options of Plasmablastic Lymphoma: Analysis of 173 Individual Patient Outcomes.《浆母细胞淋巴瘤的新兴治疗选择：173 例患者个体结局分析》
Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):e255-e263. doi: 10.1016/j.clml.2020.11.025. Epub 2020 Dec 3.
8
B-cell maturation antigen expression across hematologic cancers: a systematic literature review.B 细胞成熟抗原在血液系统恶性肿瘤中的表达：系统文献回顾。
Blood Cancer J. 2020 Jun 30;10(6):73. doi: 10.1038/s41408-020-0337-y.
9
Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma.骨髓瘤新型嵌合抗原受体T细胞疗法的靶点——B细胞成熟抗原的定量分析
Leuk Res. 2018 Aug;71:106-111. doi: 10.1016/j.leukres.2018.07.015. Epub 2018 Jul 18.
10
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.硼替佐米联合EPOCH方案作为浆母细胞淋巴瘤患者的一线治疗有效。
Br J Haematol. 2019 Feb;184(4):679-682. doi: 10.1111/bjh.15156. Epub 2018 Mar 12.